Department of Cardiology (S.N., T.G.L., C.K., F.B., C.K., D.L., D.K.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.
Department of Radiology (B.L., F.P.), Univ.Lille, CHU Lille, Heart and Lung Institute, F-59000 Lille, France.
Circ Arrhythm Electrophysiol. 2022 Sep;15(9):e010955. doi: 10.1161/CIRCEP.122.010955. Epub 2022 Sep 8.
Stereotactic body radiotherapy (SBRT) has been reported as a safe and efficient therapy for treating refractory ventricular tachycardia (VT) despite optimal medical treatment and catheter ablation. However, data on the use of SBRT in patients with electrical storm (ES) is lacking. The aim of this study was to assess the clinical outcomes associated with SBRT in the context of ES.
This retrospective study included patients who underwent SBRT in the context of ES from March 2020 to March 2021 in one tertiary center (CHU Lille). The target volume was delineated according to a predefined workflow. The efficacy was assessed with the following end points: sustained VT recurrence, VT reduced with antitachycardia pacing, and implantable cardioverter defibrillator shock.
Seventeen patients underwent SBRT to treat refractory VT in the context of ES (mean 67±12.8 age, 59% presenting ischemic heart disease, mean left ventricular ejection fraction: 33.7± 9.7%). Five patients presented with ES related to incessant VT. Among these 5 patients, the time to effectiveness ranged from 1 to 7 weeks after SBRT. In the 12 remaining patients, VT recurrences occurred in 7 patients during the first 6 weeks following SBRT. After a median 12.5 (10.5-17.8) months follow-up, a significant reduction of the VT burden was observed beyond 6 weeks (-91% [95% CI, 78-103]), <0.0001). The incidence of implantable cardioverter defibrillator shock and antitachycardia pacing was 36% at 1 year.
SBRT is associated with a significant reduction of the VT burden in the event of an ES; however, prospective randomized control trials are needed. In patients without incessant VT, recurrences are observed in half of patients during the first 6 weeks. VT tolerance and implantable cardioverter defibrillator programming adjustments should be integrated as part of an action plan defined before SBRT for each patient.
立体定向体放射治疗(SBRT)已被报道为一种安全有效的治疗方法,用于治疗尽管接受了最佳药物治疗和导管消融仍难治的室性心动过速(VT)。然而,关于 SBRT 在电风暴(ES)患者中的应用的数据尚缺乏。本研究的目的是评估 SBRT 在 ES 背景下的临床结果。
这项回顾性研究纳入了 2020 年 3 月至 2021 年 3 月期间在一家三级中心(里尔大学医疗中心)接受 SBRT 治疗 ES 的患者。根据预定义的工作流程来勾画靶区。疗效通过以下终点来评估:持续性 VT 复发、抗心动过速起搏后 VT 减少和植入式心脏复律除颤器电击。
17 例患者因难治性 VT 在 ES 背景下接受 SBRT 治疗(平均年龄 67±12.8 岁,59%为缺血性心脏病,平均左心室射血分数:33.7±9.7%)。5 例患者因无休止 VT 出现 ES。在这 5 例患者中,SBRT 后 1 至 7 周起效。在其余 12 例患者中,7 例患者在 SBRT 后 6 周内出现 VT 复发。中位随访 12.5(10.5-17.8)个月后,在 6 周后 VT 负荷显著降低(-91%[95%CI,78-103],<0.0001)。在 1 年时,植入式心脏复律除颤器电击和抗心动过速起搏的发生率为 36%。
SBRT 与 ES 时 VT 负荷的显著降低相关;然而,需要前瞻性随机对照试验。在无无休止 VT 的患者中,在最初 6 周内,有一半患者出现复发。在为每位患者制定 SBRT 前的行动计划时,应纳入 VT 耐受性和植入式心脏复律除颤器编程调整。